ovarian, fallopian tubal, primary peritneal, uterus corpus cancer
Conditions
Interventions
operation,chemotherpy
Sponsors
School of Medicine, Chiba University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Patients with a histological diagnosis of ovarian cancer (including fallopian tube, or primary peritoneal carcinoma) and uterus corpus cancer 2)Patients who are 20 years old or older and younger than 80 years old at the enrollment 3)Performance status:ECOG 0-2 4)Adequate bone marrow, renal, and hepatic function 5)Patients who are expected to survive more than 3 months. 6)Patients who have signed an approved informed consent.
Exclusion criteria
Exclusion criteria: 1)Patients who have a history of hypersensitivity to gemcitabine and irinotecan. 2)Patients with active infection 3)Patients with severe complications (Heart disease, uncontrolleddiabetes, malignant hypertension, or bleeding tendency) 4)Patients with other cancer within the past 5 years 5)Patients with myocardial infarction within 6 months or angina attack. 6)Patients who are inappropriate to enter this study with any safety reasons,judged by the treating physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival,toxicity | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | — |
Countries
Japan
Contacts
Public ContactShinichi Tate , M.D.
Chiba University Hospital Department of Gynecology
Outcome results
None listed